Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

P BCMA 101

Next Previous
Search
Drug Profile

P BCMA 101

Alternative Names: B-cell-maturation antigen-specific CAR T-cells; CARTyrin T cell product; P-BCMA-101

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poseida Therapeutics
  • Developer Janssen Biotech; Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
  • 27 Apr 2022 Poseida Therapeutics terminates a phase I/II PRIME trial in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) early to focus on an allogeneic BCMA CAR-T program (NCT03288493)
  • 13 Dec 2021 Updated safety and efficacy data from the phase I/II Prime trial in Multiple myeloma released by Poseida Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top